MedTrace Logo

Trilateral Retinoblastoma: Incidence and Outcomes

NCT06367530 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 4351

Last updated 2024-04-16

No results posted yet for this study

Summary

Patients with heritable retinoblastoma are at risk to develop an intracranial brain tumor, which is often fatal. The investigators intend to look at the incidence and survival of trilateral retinoblastoma (which is a brain tumor that can either be located in the pineal gland or elsewhere in the brain) in retinoblastoma patients globally. All retinoblastoma patients from participating centers will be included. The investigators hypothesize that the apparent incidence of trilateral retinoblastoma (especially the usually later diagnosed pineal trilateral retinoblastoma) in low-income countries will be lower because of low chances of surviving the ocular tumors at about 50% and also because of possible under-diagnosis. Therefore, as retinoblastoma care improves in low-income countries the incidence of (pineal) trilateral retinoblastoma might go up. Knowledge about incidence and survival can help improve health practices in parts of the world where this might be needed. Therefore this global study firstly aims 1) to evaluate survival after trilateral retinoblastoma and factors influencing survival and 2) to evaluate incidence of trilateral retinoblastoma by country income level. The study will run from 2024 through 2027.

Conditions

  • Trilateral Retinoblastoma
  • Retinoblastoma

Interventions

DIAGNOSTIC_TEST

Incidence and survival of trilateral retinoblastoma and the differences globally

The detection and survival of trilateral retinoblastoma around the world and for instance differences between high- and low-income countries in terms of incidence and survival.

Sponsors & Collaborators

  • Amsterdam UMC, location VUmc

    lead OTHER

Principal Investigators

  • Marcus de Jong, MD PhD · Amsterdam UMC

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2027-12-31
Completion
2029-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06367530 on ClinicalTrials.gov